SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

05 Feb 2026 Evaluate
The quarter ended December 2025 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 339.31 millions.The Net Loss for the quarter ended December 2025 is Rs. -48.42 millions as compared to Net Loss of Rs. -39.29 millions of corresponding quarter ended December 2024 Operating profit Margin for the quarter ended December 2025 further decreased to -40.76% as compared to -38.69% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 339.31 336.94 0.70 633.12 610.70 3.67 1092.99 396.42 175.72
Other Income 0.00 0.00 0.00 1.69 0.22 668.18 13.09 0.42 3016.67
PBIDT -40.76 -38.69 5.35 -153.68 -70.54 117.86 -86.84 -96.54 -10.05
Interest 13.91 3.88 258.51 29.69 14.86 99.80 36.14 26.61 35.81
PBDT -54.67 -42.57 28.42 -183.49 -85.40 114.86 -125.68 -122.78 2.36
Depreciation 8.59 7.06 21.67 25.63 20.15 27.20 17.82 15.94 11.79
PBT -63.26 -49.63 27.46 -209.12 -105.55 98.12 -143.50 -138.72 3.45
TAX -14.84 -10.34 43.52 -50.33 -24.07 109.10 -40.53 -103.92 -61.00
Deferred Tax -14.84 -10.34 43.52 -50.33 -24.07 109.10 -42.13 -103.92 -59.46
PAT -48.42 -39.29 23.24 -158.79 -81.48 94.88 -102.97 -34.80 195.89
Equity 369.84 369.84 0.00 369.84 369.84 0.00 369.84 334.84 10.45
PBIDTM(%) -12.01 -11.48 4.61 -24.27 -11.55 110.15 -7.95 -24.35 -67.37

Oxygenta Pharma Share Price

57.45 1.22 (2.17%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×